(Q34467245)

2 August 2017

Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats (English)

1 reference

2 August 2017

1 reference

1 reference

O Valverde

1

1 reference

PubMed ID

9578139

2 August 2017

B P Roques

series ordinal

2

1 reference

PubMed ID

9578139

2 August 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

2 August 2017

4

1 reference

inferred from page(s)

published in

Neuroscience Letters

1 reference

2 August 2017

244

1 reference

2 August 2017

1

1 reference

2 August 2017

37-40

1 reference

Conditioned place preference produced by infusion of Met-enkephalin into the medial preoptic area.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Heterogeneity of CCK-B receptors involved in animal models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Occurrence of two cholecystokinin binding sites in guinea-pig brain cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Evidence for the Neuropeptide Cholecystokinin as an Antagonist of Opiate Analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Evidence for coexistence of dopamine and CCK in meso-limbic neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Drug reinforcement studied by the use of place conditioning in rat

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Tolerance and selective cross-tolerance to the motivational effects of opioids.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2898%2900118-9

7 January 2021

10.1016/S0304-3940(98)00118-9

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

9578139